Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRD Adapted Therapy With Venetoclax-Obinutuzumab +/- Acalabrutinib in Relapsed or Refractory CLL/SLL
NCT04560322Phase 2Active, not recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Oct 2020
- Primary completion
- Mar 2028
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, obinutuzumab, acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), sponsored by Massachusetts General Hospital. Started Oct 2020; status: active, not recruiting.
02
Drugs
venetoclaxobinutuzumabacalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04560322.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04560322.